The Diagnostics Power Play: Metropolis Healthcare Acquires Scientific Pathology

Unknown Apr 02, 2026 1 Views

Metropolis Healthcare Limited, India's second-largest chain of pathology laboratories, is further consolidating its position in the diagnostics space through strategic acquisitions. The company recently announced the acquisition of Scientific Pathology, an Agra-based diagnostic chain, to grow its business-to-consumer (B2C) network in western Uttar Pradesh. There is no specific information available on an agreement to acquire the DAPIC business.

Key Highlights:

Scientific Pathology Acquisition: Metropolis bought out Scientific Pathology for a consideration of ₹55 crore to ₹83 crore to strengthen its foothold in western Uttar Pradesh. The acquisition is part of Metropolis' strategy of adding regional diagnostic chains to its network.
Core Diagnostics Acquisition: Prior to this, Metropolis had purchased Core Diagnostics, a niche cancer diagnostics player, for ₹246.8 crore to bolster its high-end cancer testing offerings and enhance its coverage in northern and eastern India.
Market Growth: These transactions are a continuation of a general trend of consolidation in India's diagnostics market with larger players spreading their wings by way of merger to expand reach and operational capacity.
Strategy of Growth: Metropolis wants to become a key player in various micro-markets in India through consolidation of regional labs under its umbrella.

The strategic growth emphasizes Metropolis' focus on reinforcing its diagnostic prowess and broadening its market coverage.

Source: Business Today, Business Standard, VCCircle

Stay Ahead – Explore Now! Google Gemini’s Nano Banana Trend: The Adorable AI Craze With A Hidden Dark Side